|
Real-time Estimate
Tradegate
01:00:12 28/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 21.66 EUR | -2.87% |
|
-2.59% | +4.00% |
| 27/08 | GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients | MT |
| 25/08 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Market Cap | 76.11B 103B 88.79B 83.34B 144B 9,866B 144B 986B 382B 4,978B 388B 380B 16,486B | P/E 2026 * |
14.4x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 95.95B 130B 112B 105B 181B 12,438B 182B 1,243B 482B 6,275B 490B 479B 20,783B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.66% | Yield 2027 * | 3.95% |
Last Transcript : GSK plc
| 1 day | -2.96% | ||
| 1 week | -2.59% | ||
| Current month | -2.37% | ||
| 1 month | -3.23% | ||
| 3 months | -1.71% | ||
| 6 months | -11.94% | ||
| Current year | +4.00% |
| 1 week | 21.84 |  | 22.37 |
| 1 month | 21.1 | | 23.61 |
| Current year | 20.27 | | 26.02 |
| 1 year | 16.55 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.87% | -2.59% | - | - | 103B | |
| -0.24% | -4.66% | +61.60% | +114.18% | 1,060B | |
| -1.40% | -0.31% | +50.77% | +62.24% | 651B | |
| -1.69% | -1.02% | +24.56% | +75.78% | 465B | |
| -1.41% | -2.21% | +38.46% | +40.30% | 365B | |
| -2.04% | -1.17% | +22.44% | +38.03% | 300B | |
| -0.72% | +0.73% | +2.24% | +12.35% | 258B | |
| -0.16% | +1.43% | +52.77% | +71.48% | 238B | |
| -3.18% | -0.42% | -17.33% | -54.39% | 210B | |
| +0.22% | +3.43% | +30.23% | +92.57% | 184B | |
| Average | -1.40% | -0.66% | +29.53% | +50.28% | 414.49B | |
| Weighted average by Cap. | -1.13% | -2.16% | +39.02% | +66.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 46.12B 39.59B 37.16B 64.05B 4,399B 64.35B 440B 170B 2,219B 173B 169B 7,351B | 35.52B 48.27B 41.43B 38.89B 67.03B 4,604B 67.35B 460B 178B 2,323B 181B 177B 7,693B |
| Net income | 5.44B 7.39B 6.34B 5.95B 10.26B 705B 10.31B 70.43B 27.3B 355B 27.74B 27.14B 1,177B | 6.48B 8.81B 7.56B 7.1B 12.24B 841B 12.3B 84.02B 32.56B 424B 33.09B 32.37B 1,405B |
| Net Debt | 19.84B 26.96B 23.14B 21.72B 37.44B 2,572B 37.62B 257B 99.62B 1,297B 101B 99.04B 4,297B | 17.06B 23.19B 19.9B 18.68B 32.2B 2,211B 32.35B 221B 85.67B 1,116B 87.06B 85.17B 3,695B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | EUR 21.84 | -2.06% | 252 |
| 26/08/26 | EUR 22.30 | +0.68% | 0 |
| 25/08/26 | EUR 22.15 | +0.64% | 0 |
| 24/08/26 | EUR 22.01 | -1.30% | 330 |
| 21/08/26 | EUR 22.30 | -0.54% | 538 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
